🔹 Adj. EPS: -$0.18 (Est. -$0.17) 🔴
🔹 Revenue: $200.7M (Est. $202.94M) 🔴; UP +35.8% YoY
🔹 Gross Profit: $122.1M (Est. $119.64M) 🟢; UP +49.7% YoY
FY25 Guidance:
🔹 Revenue: ~$1.24B (Est. $1.048B) 🟢; UP ~79% YoY
🔹 Adjusted EBITDA: ~$5M (Improvement of ~$110M over 2024)
Segment Performance (Q4'24):
Genomics
🔹 Revenue: $120.4M; UP +30.6% YoY
🔹 Unit Growth: UP +22.5% YoY
Data & Services
🔹 Revenue: $80.2M; UP +44.6% YoY
Key Metrics:
🔹 Net Revenue Retention: 140%
🔹 Total Remaining Contract Value: $940M
🔹 Adj EBITDA: -$7.8M (Est. -$6.57M) 🔴 (Improved from -$35.1M YoY)
🔹 Net Loss: -$13M (Est. -$28.3M) 🟢 (Improved from -$50.5M YoY)
🔹 Gross Margin: 60.8% (Est. 59.08%) 🟢
Strategic Updates & Announcements:
🔸 Closed Ambry Genetics acquisition on Feb 3, 2025.
🔸 National launch of xT CDx (FDA-approved NGS-based diagnostic) with $4,500/test reimbursement.
🔸 CMS approval for Tempus ECG-AF algorithm reimbursement at $138/algorithm.
🔸 Signed in-network agreements with Blue Cross Blue Shield of Illinois, Blue Shield of California, and Avalon Healthcare.
🔸 Expanded network to ~3,000 providers in the U.S.
CEO Eric Lefkofsky Commentary:
🔸 "Our 2024 performance highlights the strength of our core businesses, with Genomics driving volume growth and Data delivering record results. AI continues to transform diagnostics, and we are well-positioned for robust revenue growth and positive Adjusted EBITDA in 2025."
